Abbott (ABT) reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants

Partial settlements of this kind are a familiar stage in mass tort litigation, where defendants historically resolve a subset of claims to test jury sentiment, cap tail exposure, or clear weaker cases before bellwether trials set the pricing benchmark for the remainder. The word 'portion' is the operative qualifier: it signals resolution of some claims rather than a global settlement, so the remaining docket, and any pending or scheduled trials, continues to carry the headline risk. In comparable product liability episodes, equities in the defendant have tended to trade less on the fact of settlement than on the implied per-claim cost relative to the liability the market had already provisioned, which means the disclosure of terms, or their absence, matters more than the announcement itself. The precedent pattern is that early partial resolutions are often followed by further tranches, and the tell is whether plaintiffs' counsel treats the terms as a floor or rejects them in favour of trial. Worth noting is that specialty formula litigation of this type has sat alongside regulatory and reputational scrutiny of the broader infant nutrition franchise, so any read-across to that segment's standing is part of the established sequence.